{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:53:36Z","timestamp":1777625616611,"version":"3.51.4"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T00:00:00Z","timestamp":1646524800000},"content-version":"am","delay-in-days":309,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0253"],"award-info":[{"award-number":["W81XWH-17-1-0253"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jpsychires.2021.02.048","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T16:46:41Z","timestamp":1614358001000},"page":"194-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Potential of cannabinoids as treatments for autism spectrum disorders"],"prefix":"10.1016","volume":"137","author":[{"given":"V.","family":"Nezgovorova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-935X","authenticated-orcid":false,"given":"C.J.","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-9216","authenticated-orcid":false,"given":"B.P.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Shanahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Uzunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Devinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4196-0596","authenticated-orcid":false,"given":"E.","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.jpsychires.2021.02.048_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2012.07.013","article-title":"Neonatal levels of cytokines and risk of autism spectrum disorders: an exploratory register-based historic birth cohort study utilizing the Danish Newborn Screening Biobank","volume":"252","author":"Abdallah","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jneuroim.2015.07.003","article-title":"Increased production of IL-17 in children with autism spectrum disorders and co-morbid asthma","volume":"286","author":"Akintunde","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","journal-title":"Mol. Autism."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-A retrospective feasibility study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbi.2010.08.003","article-title":"Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome","volume":"25","author":"Ashwood","year":"2011","journal-title":"Brain Behav. Immun."},{"issue":"6","key":"10.1016\/j.jpsychires.2021.02.048_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6706a1","article-title":"Prevalence of autism spectrum disorder among children aged 8 Years - autism and developmental disabilities monitoring network, 11 sites, United States, 2014","volume":"67","author":"Baio","year":"2018","journal-title":"MMWR Surveill. Summ."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2174\/138955709787847921","article-title":"Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration","volume":"9","author":"Basavarajappa","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fnbeh.2012.00009","article-title":"The endocannabinoid system: an overview","volume":"6","author":"Battista","year":"2012","journal-title":"Front. Behav. Neurosci."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1017\/S003329171400172X","article-title":"The epidemiology and global burden of autism spectrum disorders","volume":"45","author":"Baxter","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yebeh.2015.04.057","article-title":"Autism and behavior in adult patients with Dravet syndrome (DS)","volume":"47","author":"Berkvens","year":"2015","journal-title":"Epilepsy Behav."},{"issue":"2","key":"10.1016\/j.jpsychires.2021.02.048_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/aur.1514","article-title":"Treatment resistant epilepsy in autism spectrum disorder: increased risk for females","volume":"9","author":"Blackmon","year":"2016","journal-title":"Autism Res."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jep.2018.09.004","article-title":"Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history","volume":"227","author":"Bonini","year":"2018","journal-title":"J. Ethnopharmacol."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/AUI.S10485","article-title":"Initial observations of elevated alpha-N-acetylgalactosaminidase activity associated with autism and observed reductions from GcProtein-Macrophage Activating Factor injections","author":"Bradstreet","year":"2012","journal-title":"Autism Insights"},{"issue":"7","key":"10.1016\/j.jpsychires.2021.02.048_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071425","article-title":"Endocannabinod signal dysregulation in autism spectrum disorders: a correlation link between inflammatory state and neuro-immune alterations","volume":"18","author":"Brigida","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jpsychires.2021.02.048_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/epi.13973","article-title":"Cannabinoids for epilepsy: what do we know and where do we go?","volume":"59","author":"Brodie","year":"2018","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.jpsychires.2021.02.048_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nm.3127","article-title":"Targeting the endocannabinoid system in the treatment of fragile X syndrome","volume":"19","author":"Busquets-Garcia","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.jpsychires.2021.02.048_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11481-015-9615-z","article-title":"Turning over a new leaf: cannabinoid and endocannabinoid modulation of immune function","volume":"10","author":"Cabral","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"1607","key":"10.1016\/j.jpsychires.2021.02.048_bib21","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nurt.2010.05.003","article-title":"Immune dysfunction in autism: a pathway to treatment","volume":"7","author":"Careaga","year":"2010","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","article-title":"Endocannabinoid signaling and synaptic function","volume":"76","author":"Castillo","year":"2012","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2040-2392-2-10","article-title":"Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces","volume":"2","author":"Chakrabarti","year":"2011","journal-title":"Mol. Autism."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s13311-015-0371-9","article-title":"Endocannabinoid signaling in autism","volume":"12","author":"Chakrabarti","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"16","key":"10.1016\/j.jpsychires.2021.02.048_bib27","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/j.jpsychires.2021.02.048_bib28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"issue":"21","key":"10.1016\/j.jpsychires.2021.02.048_bib29","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bbi.2016.07.152","article-title":"Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling","volume":"58","author":"Doenni","year":"2016","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1017\/S1092852916000262","article-title":"Neurodevelopmental disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11","volume":"21","author":"Doernberg","year":"2016","journal-title":"CNS Spectr."},{"issue":"10","key":"10.1016\/j.jpsychires.2021.02.048_bib33","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40263-019-00669-5","article-title":"Modulation of the endocannabinoid and oxytocinergic systems as a potential treatment approach for social anxiety disorder","volume":"33","author":"Dos Santos","year":"2019","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/jcpp.12829","article-title":"Examining bidirectional effects between the autism spectrum disorder (ASD) core symptom domains and anxiety in children with ASD","volume":"59","author":"Duvekot","year":"2018","journal-title":"JCPP (J. Child Psychol. Psychiatry)"},{"issue":"8","key":"10.1016\/j.jpsychires.2021.02.048_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrn3978","article-title":"Immune mediators in the brain and peripheral tissues in autism spectrum disorder","volume":"16","author":"Estes","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.neuron.2013.02.036","article-title":"Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling","volume":"78","author":"Foldy","year":"2013","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/bmm.13.158","article-title":"Metabolic pathology of autism in relation to redox metabolism","volume":"8","author":"Frye","year":"2014","journal-title":"Biomarkers Med."},{"issue":"Suppl. 2","key":"10.1016\/j.jpsychires.2021.02.048_bib39","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1542\/peds.2015-2851K","article-title":"Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis","volume":"137","author":"Fung","year":"2016","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s13311-015-0370-x","article-title":"An overview of products and bias in research","volume":"12","author":"Gloss","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jpsychires.2021.02.048_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ntt.2012.07.006","article-title":"Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment","volume":"36","author":"Goines","year":"2013","journal-title":"Neurotoxicol. Teratol."},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/aur.1665","article-title":"Serotonin neuron abnormalities in the BTBR mouse model of autism","volume":"10","author":"Guo","year":"2017","journal-title":"Autism Res."},{"issue":"6","key":"10.1016\/j.jpsychires.2021.02.048_bib43","first-page":"CE01","article-title":"Role of endocannabinoids on neuroinflammation in autism spectrum disorder prevention","volume":"11","author":"Habib","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"issue":"6","key":"10.1016\/j.jpsychires.2021.02.048_bib44","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/1362361314545685","article-title":"Evidence-based, parent-mediated interventions for young children with autism spectrum disorder: the case of restricted and repetitive behaviors","volume":"19","author":"Harrop","year":"2015","journal-title":"Autism"},{"issue":"11","key":"10.1016\/j.jpsychires.2021.02.048_bib45","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1007\/s10803-015-2511-9","article-title":"Does gender moderate core deficits in ASD? An investigation into restricted and repetitive behaviors in girls and boys with ASD","volume":"45","author":"Harrop","year":"2015","journal-title":"J. Autism Dev. Disord."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bph.12321","article-title":"Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism","volume":"170","author":"Hill","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fncel.2018.00234","article-title":"Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3(r451C) mouse model of autism","volume":"12","author":"Hosie","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/B978-0-12-418700-9.00009-5","article-title":"Immune dysregulation in autism spectrum disorder","volume":"113","author":"Hsiao","year":"2013","journal-title":"Int. Rev. Neurobiol."},{"issue":"11","key":"10.1016\/j.jpsychires.2021.02.048_bib50","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem. Neurosci."},{"issue":"8","key":"10.1016\/j.jpsychires.2021.02.048_bib51","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.imbio.2009.12.006","article-title":"Interaction between cytokines, cannabinoids and the nervous system","volume":"215","author":"Jean-Gilles","year":"2010","journal-title":"Immunobiology"},{"issue":"10","key":"10.1016\/j.jpsychires.2021.02.048_bib52","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s10803-014-2126-6","article-title":"Epilepsy among children and adolescents with autism spectrum disorders: a population-based study","volume":"44","author":"Jokiranta","year":"2014","journal-title":"J. Autism Dev. Disord."},{"issue":"6","key":"10.1016\/j.jpsychires.2021.02.048_bib53","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/aur.1316","article-title":"Repetitive behavior and restricted interests in young children with autism: comparisons with controls and stability over 2 years","volume":"6","author":"Joseph","year":"2013","journal-title":"Autism Res."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ph10040095","article-title":"Microglia M2A polarization as potential link between food allergy and autism spectrum disorders","volume":"10","author":"Kalkman","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"42","key":"10.1016\/j.jpsychires.2021.02.048_bib55","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol. Autism."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbr.2013.04.043","article-title":"Alterations in the endocannabinoid system in the rat valproic acid model of autism","volume":"249","author":"Kerr","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11481-005-9007-x","article-title":"Cannabinoid-induced immune suppression and modulation of antigen-presenting cells","volume":"1","author":"Klein","year":"2006","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"Pt 3","key":"10.1016\/j.jpsychires.2021.02.048_bib60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2788.2005.00732.x","article-title":"The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders","volume":"50","author":"Lecavalier","year":"2006","journal-title":"J. Intellect. Disabil. Res."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib61","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1037\/a0023341","article-title":"Restricted and repetitive behaviors in autism spectrum disorders: a review of research in the last decade","volume":"137","author":"Leekam","year":"2011","journal-title":"Psychol. Bull."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0043-122240","article-title":"Pharmacological foundations of cannabis chemovars","volume":"84","author":"Lewis","year":"2018","journal-title":"Planta Med."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pharmthera.2010.10.006","article-title":"Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas","volume":"129","author":"Li","year":"2011","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.jpsychires.2021.02.048_bib64","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jmedgenet-2016-104487","article-title":"Genetics implicate common mechanisms in autism and schizophrenia: synaptic activity and immunity","volume":"54","author":"Liu","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fneur.2015.00107","article-title":"The role of epigenetic change in autism spectrum disorders","volume":"6","author":"Loke","year":"2015","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-publhealth-031816-044318","article-title":"The changing epidemiology of autism spectrum disorders","volume":"38","author":"Lyall","year":"2017","journal-title":"Annu. Rev. Publ. Health"},{"issue":"7","key":"10.1016\/j.jpsychires.2021.02.048_bib67","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/npp.2010.19","article-title":"Abnormal mGlu 5 receptor\/endocannabinoid coupling in mice lacking FMRP and BC1 RNA","volume":"35","author":"Maccarrone","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.jpsychires.2021.02.048_bib68","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ejn.13705","article-title":"The neurobiological bases of autism spectrum disorders: the R451C-neuroligin 3 mutation hampers the expression of long-term synaptic depression in the dorsal striatum","volume":"47","author":"Martella","year":"2018","journal-title":"Eur. J. Neurosci."},{"issue":"6","key":"10.1016\/j.jpsychires.2021.02.048_bib69","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease","volume":"79","author":"Martin-Moreno","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib70","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/mp.2014.59","article-title":"Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis","volume":"20","author":"Masi","year":"2015","journal-title":"Mol. Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2021.02.048_bib71","article-title":"Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation","volume":"36","author":"Mastinu","year":"2018","journal-title":"Horm. Mol. Biol. Clin. Invest."},{"issue":"2","key":"10.1016\/j.jpsychires.2021.02.048_bib72","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/1362361318755318","article-title":"Factors associated with DSM-5 severity level ratings for autism spectrum disorder","volume":"23","author":"Mazurek","year":"2019","journal-title":"Autism"},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib73","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jpeds.2013.06.050","article-title":"Prenatal valproate exposure is associated with autism spectrum disorder and childhood autism","volume":"163","author":"Meador","year":"2013","journal-title":"J. Pediatr."},{"issue":"18","key":"10.1016\/j.jpsychires.2021.02.048_bib74","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1111\/bph.14435","article-title":"Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling","volume":"175","author":"Melancia","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib76","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.neuron.2015.07.033","article-title":"Excitatory\/inhibitory balance and circuit homeostasis in autism spectrum disorders","volume":"87","author":"Nelson","year":"2015","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib77","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/157015911795017047","article-title":"Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders","volume":"9","author":"Onaivi","year":"2011","journal-title":"Curr. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbi.2011.08.007","article-title":"The role of immune dysfunction in the pathophysiology of autism","volume":"26","author":"Onore","year":"2012","journal-title":"Brain Behav. Immun."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib79","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.jpsychires.2021.02.048_bib80","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/02646830500381930","article-title":"Immunity, neuroglia and neuroinflammation in autism","volume":"17","author":"Pardo","year":"2005","journal-title":"Int. Rev. Psychiatr."},{"issue":"2","key":"10.1016\/j.jpsychires.2021.02.048_bib81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the treatment of epilepsy: hard evidence at last?","volume":"7","author":"Perucca","year":"2017","journal-title":"J. Epilepsy Res."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib82","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2018.08.030","article-title":"Cannabidiol as a suggested candidate for treatment of autism spectrum disorder","volume":"89","author":"Poleg","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2021.02.048_bib83","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.lfs.2019.03.053","article-title":"Cannabidiol: recent advances and new insights for neuropsychiatric disorders treatment","volume":"224","author":"Premoli","year":"2019","journal-title":"Life Sci."},{"issue":"16","key":"10.1016\/j.jpsychires.2021.02.048_bib84","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1111\/bph.13186","article-title":"The role of cannabinoids in adult neurogenesis","volume":"172","author":"Prenderville","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.jpsychires.2021.02.048_bib85","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2217\/bmm.14.39","article-title":"Potential cytokine biomarkers in autism spectrum disorders","volume":"8","author":"Rose","year":"2014","journal-title":"Biomarkers Med."},{"issue":"7","key":"10.1016\/j.jpsychires.2021.02.048_bib86","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1523\/JNEUROSCI.4212-08.2009","article-title":"Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels","volume":"29","author":"Ryan","year":"2009","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib87","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1362361313510069","article-title":"Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder","volume":"19","author":"Scahill","year":"2015","journal-title":"Autism"},{"issue":"9","key":"10.1016\/j.jpsychires.2021.02.048_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.182","article-title":"Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid","volume":"6","author":"Servadio","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.jpsychires.2021.02.048_bib89","doi-asserted-by":"crossref","first-page":"F376","DOI":"10.1152\/ajprenal.00239.2012","article-title":"Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors","volume":"304","author":"Silva","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"11","key":"10.1016\/j.jpsychires.2021.02.048_bib90","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1007\/s10803-013-1824-9","article-title":"Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders","volume":"43","author":"Siniscalco","year":"2013","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib91","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1742-2094-11-78","article-title":"The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages","volume":"11","author":"Siniscalco","year":"2014","journal-title":"J. Neuroinflammation"},{"issue":"10","key":"10.1016\/j.jpsychires.2021.02.048_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140638","article-title":"Increased cortical inhibition in autism-linked neuroligin-3r451C mice is due in part to loss of endocannabinoid signaling","volume":"10","author":"Speed","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jpsychires.2021.02.048_bib93","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0079-6123(08)00433-0","article-title":"Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis","volume":"170","author":"Steiner","year":"2008","journal-title":"Prog. Brain Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib94","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.13598","article-title":"Prevalence and risk factors for autism spectrum disorder in epilepsy: a systematic review and meta-analysis","volume":"60","author":"Strasser","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"Pt 3","key":"10.1016\/j.jpsychires.2021.02.048_bib95","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1042\/bj20040031","article-title":"Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D","volume":"380","author":"Sun","year":"2004","journal-title":"Biochem. J."},{"issue":"10125","key":"10.1016\/j.jpsychires.2021.02.048_bib96","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2021.02.048_bib97","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/5584_2015_145","article-title":"Inflammatory activity in autism spectrum disorder","volume":"861","author":"Tonhajzerova","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib99","first-page":"61","article-title":"Molecular pharmacology of phytocannabinoids","volume":"103","author":"Turner","year":"2017","journal-title":"Prog. Chem. Org. Nat. Prod."},{"issue":"3","key":"10.1016\/j.jpsychires.2021.02.048_bib100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3109\/15622975.2015.1085597","article-title":"Excitatory\/inhibitory imbalance in autism spectrum disorders: implications for interventions and therapeutics","volume":"17","author":"Uzunova","year":"2016","journal-title":"World J. Biol. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib101","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.20315","article-title":"Neuroglial activation and neuroinflammation in the brain of patients with autism","volume":"57","author":"Vargas","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib102","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2018.07.029","article-title":"Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome","volume":"140","author":"Vigli","year":"2018","journal-title":"Neuropharmacology"},{"issue":"45","key":"10.1016\/j.jpsychires.2021.02.048_bib103","doi-asserted-by":"crossref","first-page":"14084","DOI":"10.1073\/pnas.1509795112","article-title":"Endocannabinoid signaling mediates oxytocin-driven social reward","volume":"112","author":"Wei","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jpsychires.2021.02.048_bib104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/can.2015.0008","article-title":"Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment","volume":"1","author":"Wei","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"issue":"11","key":"10.1016\/j.jpsychires.2021.02.048_bib105","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1007\/s10803-017-3153-x","article-title":"Characterization of medication use in a multicenter sample of pediatric inpatients with autism spectrum disorder","volume":"48","author":"Wink","year":"2018","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.jpsychires.2021.02.048_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107736","article-title":"Targeting the inhibition of fatty acid amide hydrolase ameliorate the endocannabinoid-mediated synaptic dysfunction in a valproic acid-induced rat model of Autism","volume":"162","author":"Wu","year":"2020","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.jpsychires.2021.02.048_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091916","article-title":"The endocannabinoid system and autism spectrum disorders: insights from animal models","volume":"18","author":"Zamberletti","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.jpsychires.2021.02.048_bib109","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/0269881119844184","article-title":"Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice","volume":"33","author":"Zamberletti","year":"2019","journal-title":"J. Psychopharmacol."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621001266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395621001266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:07:22Z","timestamp":1777421242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395621001266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":98,"alternative-id":["S0022395621001266"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.02.048","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential of cannabinoids as treatments for autism spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2021.02.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}